News

September 19, 2018September 19, 2018

Rituxan-Revlimid Combo Effective in Treating Advanced Follicular Lymphoma, Study Shows

News

Patients with previously untreated follicular lymphoma may soon be able to replace a regimen of chemotherapy and Rituxan (rituximab) with Rituxan and Revlimid (lenalidomide) after a Phase 3 trial showed similar effectiveness for ... Read more

September 18, 2018

Verastem Launches Phase 1/2 Trial to Evaluate Duvelisib-Venclexta Combo in CLL/SLL Patients

News

Verastem Oncology has dosed the first patient in its Phase 1/2 trial testing a combination of duvelisib and Venclexta (venetoclax) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who failed ... Read more

September 14, 2018

Zevalin Becomes Available in Canada for Relapsed or Refractory Non-Hodgkin’s Lymphomas

News

Patients in Canada with relapsed or refractory low-grade or follicular B-cell non-Hodgkin’s lymphoma, who produce the CD20 factor, can now be treated with Zevalin (ibritumomab tiuxetan). Servier Canada, Zevalin’s manufacturer, ... Read more

September 13, 2018

Mouse Study Finds Potential Therapeutic Target for Anaplastic Large-cell Lymphoma

News

A cellular protein called TYK2 plays a key role in tumor development and survival in anaplastic large-cell lymphoma (ALCL), according to a new study. The finding suggests that targeting TYK2 ... Read more

September 12, 2018

Corticosteroid Use May Cause Bone Side Effects in Hodgkin’s Lymphoma Patients, Study Suggests

News

Corticosteroid use is among the risk factors leading to osteonecrosis — a painful, bone-disrupting condition — in Hodgkin’s lymphoma patients, a large retrospective analysis shows. Given that no proven interventions ... Read more

September 11, 2018

Adcetris-Chemotherapy Combo Improves Survival Rates in Elderly Hodgkin’s Patients, Phase 2 Trial Shows

News

Adding Adcetris (brentuximab vedotin) to standard chemotherapy significantly improves responses and survival rates of elderly patients with newly diagnosed Hodgkin’s lymphoma, a Phase 2 study shows. In the trial, 90% of ... Read more

September 10, 2018

Investigational Therapy TAK-659 Targets Lymphomas Linked to Epstein-Barr Virus, Mouse Study Shows

News

TAK-659, an investigational compound being developed by Takeda Pharmaceuticals, is able to target lymphomas associated with Epstein-Barr virus (EBV) infection, preventing their growth and spread, a mouse study shows. The ... Read more

September 7, 2018

Common Therapy for Rare Blood Cancer May Activate ‘Dormant’ Lymphoma, Study Suggests

News

Treatment of myelofibrosis, a rare type of blood cancer, with Jakafi (ruxolitinib) gives a patient 16 times the risk of developing aggressive B-cell lymphoma, through the activation of a pre-existing ... Read more

September 6, 2018

New Drug Application for Investigational Hodgkin’s Lymphoma Therapy Tislelizumab Accepted in China

News

China’s regulatory agency recently accepted BeiGene’s new drug application (NDA) for tislelizumab, its investigational immune checkpoint inhibitor, for the potential treatment of patients with classical Hodgkin’s lymphoma who failed to respond or whose disease ... Read more

September 5, 2018

Follicular Lymphoma Patients with Private Insurance in US Show Better Overall Survival Rates Than Others, Study Reports

News

Follicular lymphoma patients in the U.S. with private insurance are about twice as likely to survive their cancer than those without health insurance or covered by public plans like Medicare or ... Read more